Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Related Keywords

Jordan ,United States ,American ,Carl Spana ,Prnewswire Palatin Technologies Inc ,Securities Exchange ,Exchange Commission ,Palatin Technologies Inc ,Peptide Therapeutics ,Glucagon Like ,Synergistic Weight Loss ,Reduced Food Intake ,Greater Glucose Control ,Diet Induced Obese ,Peptide Therapeutics Symposium ,Agonists Effect ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Palatin Technologies ,Nc ,